This study aims to find out if a new treatment, **Belantamab Mafodotin with Lenalidomide and Dexamethasone (BRd)**, is better than another treatment, **Daratumumab with Lenalidomide and Dexamethasone (DRd)**, for people with **Newly Diagnosed Multiple Myeloma (NDMM)** who cannot have a **stem cell transplant**. Multiple myeloma is a type of blood cancer. In this study, researchers want to see if BRd helps people live longer without the cancer getting worse and if it helps more people have less cancer left in their body, called **minimal residual disease (MRD) negative status**. **Key Points:** - Participants must be at least 18 years old and have NDMM that needs treatment. - The study involves taking medications and visiting the study center for check-ups. - Participants should not have had certain surgeries or other serious medical conditions recently. This study is essential because it could lead to better treatments for people who cannot undergo more intensive therapies like stem cell transplants. Participants will help researchers learn more about effective treatments for multiple myeloma.